Company / EPS (Diluted)
Esperion Therapeutics, Inc. EPS (Diluted) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.11
FY2025
5-year range
-$3.59 / -$0.11
FY2021-FY2025
Trend
+60.7%
vs FY2024
Sector context
#54 of 204
Health Care
What the data says
At $-0.11, Esperion Therapeutics, Inc.'s eps (diluted) ranks #54 of 204 in the Health Care sector. EPS (Diluted) has increased for 4 consecutive years, from $-3.59 in FY2021 to $-0.11 in FY2025.
Based on SEC 10-K filings.
-0.11 in FY2025.
Improved from $-2.03 to $-0.11 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#54 of 204 in Health CareTop 26% of 204This company -$0.11 Sector average -$0.89
▼
+87.6% above sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s eps (diluted) has grown for 4 consecutive years.
- In FY2025, eps (diluted) increased 60.7% year-over-year.
- Ranks #54 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.11 | +60.7% |
| FY2024 | -$0.28 | +86.2% |
| FY2023 | -$2.03 | +42.3% |
| FY2022 | -$3.52 | +1.9% |
| FY2021 | -$3.59 | -183.1% |
| FY2020 | $4.32 | +40.7% |
| FY2019 | $3.07 | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026